论文部分内容阅读
目的 研究来氟米特治疗活动期类风湿关节炎的临床疗效和安全性。方法 治疗组(来氟米特 )和对照组 (甲氨喋呤 )各 2 4例分别使用来氟米特、甲氨喋呤治疗。参与疗效综合评估的指标有晨僵、关节疼痛水平、关节疼痛数、关节肿胀数、医生及病人的评估、血沉、C-反应蛋白、类风湿因子滴度。以总改善百分率对疗效进行综合评估。结果 治疗 12周 ,治疗组和对照组病人各项观察指标均有明显改善。总疗效来氟米特组为 91.67% ,甲氨喋呤为 70 .84 %。治疗组和对照组出现的药物不良反应分别为 2 0 .83%、50 .0 0 %。结论 来氟米特和甲氨喋呤治疗活动性类风湿关节炎均有明显疗效 ,但来氟米特的副作用较小
Objective To study the clinical efficacy and safety of leflunomide in the treatment of active rheumatoid arthritis. Methods The treatment group (leflunomide) and the control group (methotrexate) each 24 cases were treated with leflunomide, methotrexate. Participants in the comprehensive evaluation of indicators of efficacy are morning stiffness, joint pain, joint pain, joint swelling, assessment of doctors and patients, ESR, C-reactive protein, rheumatoid factor titers. A comprehensive assessment of the efficacy was made with the percentage of total improvement. Results The treatment of 12 weeks, the treatment group and the control group of patients were significantly improved the observation of indicators. The total efficacy of leflunomide group was 91.67%, methotrexate was 70.84%. Adverse drug reactions in the treatment group and control group were 20.83% and 50.0%, respectively. Conclusions Leflunomide and methotrexate are effective in the treatment of active rheumatoid arthritis, but the side effects of leflunomide are small